Is it time for AI for drug discovery as a service?

October 25, 2021 | Case Study

Despite the value of AI to the pharmaceutical industry in the drug discovery space, significant barriers to its adoption remain. One of the major barriers lies in developing the relevant AI capabilities to tackle questions around novel target identification, lead identification and optimization, safety, and bioavailability and metabolic stability, to name a few. Big pharma has, for the most part, looked at investing heavily in these capabilities internally, launching open innovation programs or acquiring promising drug discovery startups. However, smaller pharmaceuticals and clinical-stage biotechnology companies are more resource-scarce, especially if there is no internal AI expertise within the core team.

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978